苏存锦

姓名: 苏存锦 

邮箱: sucjgh@vip.163.com 

电话: 15862352904

Professional Experience 

09/2023-Present Postdoctoral Fellow 

                           Laboratory of Dr. Qingchun Tong 

                           Center for Neuroimmunology and Glial Biology 

                           University of Texas Health Science Center at Houston 

                           Research Interests: Neural Control of Feeding and Metabolism 

08/2013-08/2023 Pharmacist 

                           Department of Pharmacy 

                           The Second Affiliated Hospital of Soochow University 

                           Domain: Therapeutic Drug Monitoring and Individualized Medication

Education 

09/2016-06/2021 Institute of Neuroscience, Soochow University, PhD 

                             Laboratory of Dr. Tong Liu 09/2010-06/2013 Department of Pharmacology, Nanjing Medical University, MS 

                             Laboratory of Dr. Gang Hu 09/2005-06/2010 School of Pharmacy, Nanjing Medical University, BS

Research Interests

     I am currently conducting postdoctoral research in the United States, focusing on the neural circuit mechanisms underlying metabolic regulation. My research aims to elucidate the key drivers of disordered feeding behavior and impaired body weight homeostasis, thereby providing a conceptual framework and identifying potential therapeutic targets for the prevention and treatment of eating disorders, obesity, and anorexia.

    To achieve these objectives, I employ a variety of animal models in combination with state-of-the-art techniques, including electrophysiology, optogenetics, chemogenetics, and in vivo imaging. I utilize the Cre-loxP mouse genetic system to enable precise, neuronspecific manipulation in the brain. In addition, adeno-associated viral (AAV) vectors carrying Cre-dependent expression constructs are delivered to specific brain regions containing Cre-expressing neurons, allowing targeted expression of exogenous tool genes, such as engineered ion channels that selectively activate or inhibit neuronal activity. Furthermore, virus-based tracing approaches are used to map defined neural circuits and investigate their roles in physiological functions and behavior. We are also exploring the use of CRISPR/Cas9 technology to achieve neuron-specific gene deletion in adult mice. Collectively, these advanced methodologies ensure the rigor of our research and enable the generation of precise and insightful mechanistic findings.

     Prior to my postdoctoral training, my research focused on the immunological mechanisms underlying neuropathic pain, as well as dysregulated autophagy in dopaminergic neurons in Parkinson’s disease. I also previously conducted research on therapeutic drug monitoring, individualized pharmacotherapy, and metabolomics.

Publications

1. Cunjin Su*, Jing Cai, Yuanzhong Xu, Benjamin R Arenkiel, Qingchun Tong*. An obligatory role for AgRP neurons in maintaining body temperature during time-restricted feeding. Metabolism. 2026:179:156595. 

2. Hailan Liu, Veronica L Li, Qingzhuo Liu, Yao Liu, Cunjin Su, Hueyxian Wong, Na Yin, Hesong Liu, Xing Fang, Kristine M McDermott, Hueyzhong Wong, Meng Yu, Longlong Tu, Jonathan C Bean, Yongxiang Li, Mengjie Wang, Yue Deng, Yuhan Shi, Olivia Z Ginnard, Yuxue Yang, Junying Han, Megan E Burt, Sanika V Jossy, Chunmei Wang, Yongjie Yang, Benjamin R Arenkiel, Dong Kong, Yang He, Jonathan Z Long, Yong Xu. Lac-Phe induces hypophagia by inhibiting AgRP neurons in mice. Nat Metab. 2025;7(10):2004-2017. 

3. Hongli Li¹ , Cunjin Su¹ , Yuanzhong Xu, Mette Q Ludwig, Jon Davis, Qingchun Tong. An alternative neural basis underlying leptin resistance. Cell Rep. 2025; 44(7):115863. 

4. Zheng Xiang, Yueyuan Wang, Yuchen Qu, Bo Lv, Junping Han, Delai Xu, Kai Fan, Cunjin Su*, Zhu Shen*，The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients. Int J Gen Med. 2024:17:297-304. 

5. Fenglun Zhao, Zheng Xiang, Junping Han, Jie Pan, Yuchen Qu, Kai Fan, Zhiqiang Wu, Delai Xu, Yunli Yu, Zhu Shen, Cunjin Su. Simultaneous quantification of nirmatrelvir/ritonavir in human serum by LC-HRMS. J Pharm Biomed Anal. 2024: 237:115796. 

6. Cunjin Su, Jiangtao Zhang, Fenglun Zhao, Delai Xu, Jie Pan, Tong Liu. Resolvin D1/N-formyl peptide receptor 2 ameliorates paclitaxel-induced neuropathic pain through the activation of IL-10/Nrf2/HO-1 pathway in mice. Front Immunol. 2023:14:1091753. 

7. Yuchen Qu, Cunjin Su, Zheng Xiang, Yueyuan Wang, Junping Han, Jie Pan, Zhu Shen. Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection. Eur J Pharm Sci. 2023:189:106535. 

8. Liwei Ni, Jianhao Xu, Fenglun Zhao, Xiaoxiao Dai, Jialong Tao, Jie Pan, Aiming Shi, Zhu Shen, Cunjin Su*, Yusong Zhang*. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo. Eur J Pharmacol. 2021: 899: 174054. 

9. Cunjin Su, Zhu Shen, Ruxiao Cui, Ya Huang, Delai Xu, Fenglun Zhao, Jie Pan, Aiming Shi, Tong Liu, Yunli Yu. Thioredoxin-Interacting Protein (TXNIP) Regulates Parkin/PINK1-mediated Mitophagy in Dopaminergic Neurons Under High-glucose Conditions: Implications for Molecular Links Between Parkinson's Disease and Diabetes. Neurosci Bull. 2020;36(4):346-358. 

10. Cunjin Su, Jianhao Xu, Xu Liu, Fenglun Zhao, Jie Pan, Aiming Shi, Duanmin Hu, Yunli Yu, Tong Liu, Yusong Zhang. X-ray induces mechanical and heat allodynia in mouse via TRPA1 and TRPV1 activation. Mol Pain. 2019:15:1744806919849201. 

11. Cunjin Su, Yu Feng, Tengteng Liu, Xu Liu, Junjie Bao, Aiming Shi, Duanmin Hu, Tong Liu, Yunli Yu. Thioredoxin-interacting protein induced α-synuclein accumulation viainhibition of autophagic flux: Implications for Parkinson's disease. CNS Neurosci Ther. 2017;23(9):717-723.

Grants 

1. NSFC Young Scientists Fund, 01/2017-12/2019, The role of thioredoxin-interacting  protein in Parkinson's disease, 81601098. 

2. Suzhou Scientists Fund, 07/2019-06/2022, Therapeutic Effects of Endoplasmic  Reticulum Stress Inhibitors on Radiation-Induced Cognitive Impairment, SYS2019058. 

3. Suzhou Scientists Fund, 07/2023-06/2026, Therapeutic Effects of HDAC10 Inhibitors  on Inflammatory Bowel Disease, SYS2023077.